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Aim: This study assessed the infectious etiology of patients hospitalized for acute exacer-
bations of chronic obstructive pulmonary disease (AECOPD) with concomitant pneumonia.
Methods: Patients admitted to medical wards in an acute hospital were recruited prospec-
tively from May 1, 2004 to April 30, 2005. Sputum culture, blood culture, paired serology,
and nasopharyngeal aspirates (NPA) viral culture and polymerase chain reaction (PCR) stud-
ies were performed. Spirometry was assessed in stable phase at 2e3 months post-hospital
discharge.
Results: Seventy eight subjects were admitted for AECOPD with concomitant pneumonia.
The mean (SD) age was 77.1 (7.5) years, with FEV1 of 41.5 (20.8)% predicted normal. Over-
all, an infectious etiology could be established in 48.7% of the subjects. Among the 71 sub-
jects with sputum collected, 40.8% had positive bacterial culture. The commonest bacteria
identified were Streptococcus pneumoniae (8[11.3%]), Pseudomonas aeruginosa (7[9.9%])
and Haemophilus influenzae (7[9.9%]). Among the 66 subjects with NPA collected, 9.0
and 12.2% had positive viral culture and PCR results, respectively. The commonest viruses
identified by NPA PCR were influenza A (4[6.1%] subjects) and rhinovirus (2[3.0%]). Paired
serology was positive in 4.4%. Patients on high dose inhaled corticosteroid (ICS)
(>1000 mcg beclomethasone-equivalent/day) had a higher rate of positive sputum bacterial
culture than those on low-medium dose of ICS (50.0% vs 18.2%, pZ 0.02).632 3493; fax: þ852 2648 9957.
hk (D.S.C. Hui).
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1110 F.W.S. Ko et al.Conclusion: An infectious etiology could be established in about half of patients hospital-
ized with AECOPD and concomitant pneumonia. The majority of identifiable causes were
bacterial. Patients on high dose ICS might have impaired airway defense as reflected by
the higher rate of positive sputum culture.
ª 2008 Elsevier Ltd. All rights reserved.Introduction
Pneumonia is a major cause of morbidity and mortality
worldwide. In the US, pneumonia is the 6th most common
cause of death and the leading cause of death among all
infectious diseases.1 In Hong Kong, pneumonia and COPD
were the 3rd and 5th leading causes of death, with mortal-
ity rates of 60 and 28.5 per 100,000 population, respec-
tively.2 An observational study in the US reported that
patients with community-acquired pneumonia (CAP) with
a diagnosis of COPD had a significantly higher 30- and 90-
day mortality than non-COPD patients.3 Recently, the use
of inhaled corticosteroids (ICS) is associated with an excess
risk of pneumonia hospitalization followed by death within
30 days, among elderly patients with COPD.4
Most studies on the etiology of CAP did not focus on
COPD patients.5e7 In addition, some studies of the infec-
tious etiology of pneumonia were conducted in the inten-
sive care unit (ICU) setting, and were again not specific
for COPD.8,9 On the other hand, many studies of the infec-
tious etiology related to AECOPD have excluded patients
with pneumonia as they were not considered as ‘‘pure’’
AECOPD.10e13 Our group has previously conducted a retro-
spective study on the sputum bacteriology of patients with
AECOPD with concomitant pneumonia,14 but the causative
role of viruses was not explored. There are currently lim-
ited data on the etiological agents in patients with AECOPD
and concomitant pneumonia.15 The aim of this study is to
assess prospectively the bacterial and viral etiology of
patients hospitalized with AECOPD and concomitant pneu-
monia. In addition, the associations between the identifi-
cation of micro-organisms in AECOPD with the use of ICS
and clinical outcomes (including mortality and need for
non-invasive positive pressure ventilation [NPPV]) were
assessed.
Methods
Subject recruitment
Patients who had been admitted to the Prince of Wales
Hospital with AECOPD and concomitant pneumonia be-
tween May 1, 2004 and April 30, 2005 were recruited for
this study. AECOPD was defined when a patient with
background COPD16 presented with at least two of the
following major symptoms (increased dyspnea, increased
sputum purulence, increased sputum volume) or one major
and one minor symptom (nasal discharge/congestion,
wheeze, sore throat, cough) for at least two consecutive
days.17,18 All chest radiographs (CXRs) were assessed by
the investigators (respiratory physicians). Pneumonia was
defined when there was radiographic evidence of chestinfection (new infiltrates and consolidation on the CXRs).
Informed written consent was obtained from each subject
and the study was approved by the research ethics commit-
tee of the Chinese University of Hong Kong.
Demographic data and management in hospital
Demographic data and length of hospital stay of patients
with AECOPD were recorded. Co-morbid conditions were
noted and scored by the Charlson index.19 The scoring of
the Charlson index ranged from 0 to 33, with a higher score
indicating more in number and severity of the co-existing
illnesses. The use of NPPV, invasive mechanical ventilation,
and ICU admission were recorded.
Microbiological examination
Expectorated sputum was collected into a sterile container
and processed and cultured according to standard pro-
cedures as described in our previous study.10,20 NPA was ob-
tained by catheter aspiration from the posterior nasal
pharyngeal space via the nostril with the patient in the sit-
ting position. NPA viral culture was performed as described
in our previous studies.10,11 For the viral PCR assessment of
the NPA, 5 groups of nested multiplex PCR assays targeting
18 respiratory viruses and three bacteria were applied as
described in our previous study.21 The viruses and bacteria
included influenza A H1N1, H3N2 and H5N1, influenza B,
parainfluenza types 1, 2, 3, 4a and 4b, respiratory syncytial
viruses (RSV) A and B, rhinovirus, enterovirus, coronaviruses
(OC43, 229E, SARS), metapneumovirus, Mycoplasma pneu-
moniae, Chlamydophila pneumoniae, Legionella pneumo-
phila and adenovirus.
Paired serum samples for serology were obtained on
admission and at 14e28 days later. The presence of
antibody specific for influenza A and B, parainfluenza 1,
2, and 3, RSV, adenovirus, M. pneumoniae, and Chlamydia
psittaci was detected by complement fixation test. Sero-
conversion or 4-fold rise in antibody titre was regarded
as evidence for current infection. Blood was cultured using
the BacT/Alert Microbial Detection System.
Follow up of progress of patients post-discharge
Spirometry pre- and post-bronchodilator was performed at
2e3 months post-discharge (stable COPD) according to the
American Thoracic Society Standard22 using the Vitalograph
(Buckingham, UK) spirometer. The updated predicted spi-
rometry values for Hong Kong Chinese were adopted.23
The patients were contacted by phone and their medical
records were reviewed 12 months later to check for any
deaths or re-admissions.
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Data were analyzed by the Statistical Package of the Social
Science (SPSS) Statistical software for Window, Version 11.5
(SPSS Inc, IL, USA). The associations between the identifi-
cation of an organism in AECOPD (bacteria in sputum,
viruses in the NPA and serology) and the lung function and
clinical outcomes of patients (mortality, NPPV use and
length of hospital stay) were assessed by ManneWhitney U
test, chi-square test and Fisher-exact test as appropriate.
Data were presented as mean (SD) and a p value of <0.05
was considered as significant.
Results
Altogether 78 subjects were admitted with the first episode
of AECOPD with concomitant pneumonia. The demographic
characteristics of the patients are shown in Table 1. Lung
function results were available for 64 patients. Twelve
patients died before the scheduled appointment for
spirometry whereas two refused to return for lung function
assessment. Among the 64 subjects with lung function
assessment, 5, 13, 23 and 23 patients had mild, moderate,
severe, and very severe COPD according to the GOLD
classification.16 Forty-two patients (53.8%) were using ICS
before hospitalization. The mean (SD) dose of ICS was
1345 (679) mcg beclomethasone-equivalent per day. ThereTable 1 Demographic characteristics of the patients
(nZ 78)
Age (yrs) 77.1 7.5
Sex (male) 66 (84.6)
Body mass index (kg/m2) 20.71 3.66
Post-bronchodilator FEV1
a (L) 0.77 0.37
Post-bronchodilator FVCa (L) 1.35 0.55
Post-bronchodilator FEV1/FVC ratio
a 0.58 0.15
Post-bronchodilator FEV1%
predicted normala (%)
41.50 20.76
Post-bronchodilator FVC1%
predicted normala (%)
51.23 19.69
Pre-morbid status
Home bound 13 (16.7)
Outgoing but could only walk
on level ground
28 (35.9)
Could climb up several fights
of stairs
37 (47.4)
Smoking status
Never-smoker 1 (1.3)
Quitted smoking 61 (78.2)
Current smoker 16 (20.5)
Home oxygen use 20 (25.6)
On inhaled corticosteroid 42 (53.8)
On oral theophylline 29 (37.2)
Received influenza vaccination
over the past 12 months
34 (43.6)
Charlson index 1.58 0.88
Data are presented as mean SD or n (%).
a Lung function was available in 64 patients.was no difference in the demographic characteristics (in-
cluding the mean lung function value) between subjects
who were on ICS and those who were not. In addition, by
stratifying subjects on ICS into two subgroups of high
(>1000 mcg beclomethasone-equivalent per day) and low-
medium (1000 mcg beclomethasone-equivalent per day)
dose of ICS, no difference in their demographic data was
observed (Supplementary Table 1). The mean (SD) dose of
the group on high dose and low-medium dose ICS were
2050.0 (223.6) and 836.4 (283.8) mcg beclomethasone-
equivalent per day, respectively.
Among our subjects, 28 (35.8%), 11 (14.1%), 7 (9.0%), 5
(6.4%), 5 (6.4%), 7 (9.0%) had history of hypertension,
cerebrovascular accident, diabetes mellitus, ischaemic
heart disease, congestive heart failure and malignancy,
respectively. All patients were managed on the general
medical wards and none required invasive mechanical
ventilation. There were no significant differences in mor-
tality in the same admission, mortality at 12 months, and
NPPV usage when comparing subjects on ICS against those
who were not, or when comparing subjects who were on
low-medium dose of ICS against those on high dose ICS
(Supplementary Table 1).
The clinical presentations of the subjects are summa-
rized in Table 2. In 10 episodes, subjects had taken antibi-
otics within 7 days before hospitalization. All subjects had
pneumonic changes on CXRs. Among them, 7 episodes had
bilateral CXR changes whereas 13 episodes had pneumonic
changes involving more than 1 lobe of the lungs. Three sub-
jects developed pleural effusion. All patients were treated
with antibiotic therapy on admission after sputum and
blood culture had been collected in the hospital.
The sputum culture results are shown in Table 3. Over-
all, 40.8% and 3.0% of the episodes had positive sputum
bacterial and mycobacterial culture, respectively. Two
out of the 8 patients (25.0%) related to Streptococcus
pneumoniae were resistant to penicillin whereas none of
theHaemophilus influenzae isolates showed beta-lactamase
activity. None had more than one bacterium isolated from
the sputum. There was no difference in the rate of positive
sputum bacterial culture in the group that had received
antibiotic in the previous week when compared to those
who did not (3/10[30.0%] vs 26/61[42.6%], pZ 0.45). Sub-
jects on ICS were not different in terms of the rate of pos-
itive sputum bacterial culture from those not on ICS (14/
39[35.9%] vs 15/32[46.9%], pZ 0.35). However, subjectsTable 2 Clinical data of the admissions (nZ 78 subjects)
Hospital stay in acute hospital (days) 8.7 6.0
Hospital stay in acuteþ convalescent
hospital (days)
16.8 12.7
Fever on admission (temperature> 37.5 C) 33 (42.3%)
WCC on admission (109/L) 14.0 5.7
Use of NPPV 15 (19.2%)
Use of mechanical ventilation 0
Admission to ICU 0
Data are presented as mean SD or n (%).
WCCZwhite cell count.
NIPVZ non-invasive positive pressure ventilation.
ICUZ intensive care unit.
Table 3 Sputum culture results
Sputum for routine culture (nZ 71) Sputum for mycobacterial culture (nZ 66)
Culture negative 42 (59.2) Mycobacterium culture negative 64 (97.0)
Streptococcus pneumonia 8 (11.3) Mycobacterium tuberculosis 1 (1.5)
Pseudomonas aeruginosa 7 (9.9) Mycobacterium kansasii 1 (1.5)
Haemophilus influenzae 7 (9.9)
Klebsiella species 2 (2.8)
Serratia species 2 (2.8)
MRSA 1 (1.4)
Stenotrophomonas maltophilia 1 (1.4)
Candida albicans 1 (1.4)
Data are presented as n (%).
There were a total of 71 and 66 episodes of AECOPD with concomitant pneumonia had sputum saved for routine bacterial culture and
mycobacterial culture, respectively.
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rial culture than those on low-medium dose of ICS (10/
20[50.0%] vs 4/22[18.2%], pZ 0.02).
The results of NPA PCR, NPA viral culture and blood
serology are shown in Table 4. The positive rates of NPA
PCR, NPA viral culture, and blood serology results were
12.2, 9.0 and 4.4%, respectively. Subjects on ICS had
a higher rate of positive viral etiologies (using the combined
method of NPA PCR, NPA viral culture and blood serology)
than those who were not (10/38[26.3%] vs 2/35[5.8%],
pZ 0.02). There was, however, no difference in the rates
of identification of viral etiologies comparing the subjects
on low-medium dose ICS against those on high dose ICS
(5/22[22.7%] vs 5/20[25.0%], pZ 0.70). There was also no
difference in the rates of positive influenza A or B viruses
(using the combined method of NPA PCR, NPA viral culture
and blood serology) among those subjects who had received
influenza vaccination within 12 months before the admis-
sion compared to those without (3/33[9.1%] vs 4/40[10%],
pZ 0.90). All episodes had blood culture performed but
none were positive. Among the 3 subjects with pleural effu-
sion, 2 had undergone pleural fluid aspiration. The pleural
fluid was exudative in nature with no bacteria identifiedTable 4 NPA PCR, viral culture and serology results
PCR (nZ 66) Influenza A (H3) 4 (6.1)
Rhinovirus 2 (3.0)a
Influenza B 1 (1.5)
Metapneumovirus 1 (1.5)
Coronavirus OC43 1 (1.5)a
Negative PCR 58 (87.8)
NPA viral culture
(nZ 66)
Influenza A 3 (6.2)
Influenza B 2 (3.0)
Herpes simplex virus type 1 1 (1.5)
Negative viral culture 60 (91.0)
Serology (nZ 45) Influenza A 1 (2.2)
RSV 1 (2.2)
Negative serology 43 (95.6)
Data are presented as n (%).
a One case had both rhinovirus and coronavirus OC43 identi-
fied in the PCR.by Gram stain or culture. Overall, the rate of positive iden-
tification by sputum culture, NPA PCR, NPA viral culture,
and blood serology was 48.7% (38/78). Three subjects
(3.8%) had both positive bacterial and viral etiology identi-
fied (positive sputum cultures and positive viruses [either
from NPA PCR, NPA viral culture or blood serology]).
Among those with bilateral pneumonia (nZ 7), 3 had
micro-organisms identified (1 H. influenzae and 2 influenza
A). For those 13 cases with pneumonic changes involving
more than 1 lobe (7 of them had bilateral pneumonia
also), 4 had bacteria (2 H. influenzae, 1 S. pneumoniae
and 1 Serratia sp.) and 3 had viruses identified (2 influenza
A and 1 metapneumovirus). None of these subjects had
both bacterial and viral etiologies identified at the same
time.
The identification of the organisms in relation to the
lung function of the subjects is shown in Table 5. There was
a trend towards a higher rate of positive sputum bacterial
culture among the subjects with FEV1< 50% predicted
than those with FEV1 50% predicted (19/45[42.2%] vs 2/
14[14.3%], pZ 0.04). However, the rate of positive sputum
bacterial culture was not different among patients with
FEV1< 30% predicted from those whose FEV1 was 30% pre-
dicted (8/20[40.0%] vs 13/39[33.3%], pZ 0.61). Similarly,
the rate of positive viral etiology was not statistically dif-
ferent between the COPD subjects with different disease
severity based on their lung function.
The hospital length of stay, need for NPPV support,
death rates in the same admission and at 12 months, and
re-admissions to hospital in 12 months were assessed in
relation to the bacteriology and virology results (Table 6).
Patients with a positive viral etiology had a higher chance
of requiring NPPV support than those without viral identifi-
cation by either NPA or serology (41.7% vs 11.5%, pZ 0.01).
The age, sex, presence of co-morbid medical illness (such
as diabetes mellitus, hypertension, cerebrovascular acci-
dent, ischaemic heart disease, congestive heart failure or
malignancy) and admissions for pneumonia in the previous
12 months had no association with the presence of bacteria
and viruses from the respiratory specimens. In addition,
the presence of co-morbidities (as defined above) had no
effect on the death rate and the length of hospital stay
when compared to the subjects without co-existing medi-
cal illness.
Table 5 The identification of the organisms in relation to the lung function
Mild to moderate COPD Severe COPD Very severe COPD
Sputum results
(nZ 59)
Episodes with lung function
performed and sputum saved
14 25 20
Streptococcus pneumonia 1 (7.1) 2 (8.0) 4 (20.0)
Pseudomonas aeruginosa 1 (7.1) 2 (8.0) 0
Haemophilus influenzae 0 3 (12.0) 2 (10.0)
Klebsiella species 0 1 (4.0) 1 (5.0)
Serratia species 0 1 (4.0) 0
MRSA 0 0 1 (5.0)
Stenotrophomonas maltophilia 0 1 (4.0) 0
Candida albicans 0 1 (4.0) 0
Negative sputum culture 12 (85.7) 14 (56.0) 12 (60.0)
NPA PCR results
(nZ 53)
Episodes with lung function
performed and with NPA saved
16 20 17
Influenza A (H3) 0 2 (10.0) 2 (11.8)
Rhinovirus 0 0 2a (11.8)
Influenza B 0 0 1 (5.9)
Metapneumovirus 1 (6.3) 0 0
Coronavirus OC43 0 0 1a (5.9)
Negative PCR 15 (93.8) 18 (90.0) 12 (70.6)
NPA viral culture
(nZ 53)
Episodes with lung function
performed and with NPA saved
16 20 17
Influenza A 0 1 (5.0) 2 (11.8)
Influenza B 1 (6.3) 0 1 (5.9)
Herpes simplex virus type 1 1 (6.3) 0 0
Negative viral culture 14 (87.5) 19 (95.0) 14 (82.4)
Serology
(nZ 41)
Episodes with lung function
performed and paired
serology saved
10 18 13
Influenza A 0 1 (5.6) 0
RSV 1 (10.0) 0 0
Negative serology 9 (90.0) 17 (94.4) 13 (100)
Data are presented as n (%).
a One episode with NPA PCR study positive for both coronavirus OC43 and rhinovirus.
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Pseudomonas aerurgina in sputumwas associated with older
age (84.9 3.7 vs 76.3 7.3, p< 0.01). Apart from that, we
could not identify any difference among certain strains of
bacteria (including P. aerurgina, H. influenzae, Klebsiella
species) in relation to the subjects’ age, body mass index,
FEV1 and long term home oxygen use.
For those cases with bilateral pneumonia, their length of
hospital stay (8.7 5.0 vs 8.7 6.2 days, pZ 0.95), NPPVuse
(28.6[2/7]% vs 18.3% (13/71)%, pZ 0.62) and death rate in
the same admission (28.6[2/7]% vs 9.9[7/71]%, pZ 0.18)
were not different from those with unilateral pneumonia.
Similarly, among those cases with pneumonia involving
more than 1 lobe, their length of hospital stay (8.8 4.5 vs
8.7 6.3days, pZ 0.93), NPPV use (30.8[4/13]% vs 16.9
[11/65]%, pZ 0.26) and death rate in the same admission
(15.3[2/13]% vs 10.8[7/65]%, pZ 0.64) were not different
from those with pneumonia that affected just 1 lobe. For
the 3 cases with both bacterial and viral etiologies (one
with MRSAþ influenza B, one with H. influenzaeþ influenza
A, one with S. pneumoniaeþ rhinovirusþ coronavirus), onepatient had required NPPV support during hospitalization
but they all survived over the next 12 months.
Discussion
To the best of our knowledge, this is the first prospective
study that has included examination of sputum bacteriology
and viral multiplex nested-PCR assessment of respiratory
specimens from patients admitted to themedical wards with
AECOPD and concomitant pneumonia. An infectious etiology
could be established in 48.7% of the episodes of admissions.
The rates of positive sputum bacterial culture and NPA viral
PCR were 40.8% and 12.2%, respectively. The commonest
bacteria identified were S. pneumoniae, P. aeruginosa and
H. influenzaewhereas the common viruses involved were in-
fluenza A and rhinovirus. Interestingly, patients on higher
dose of ICS (>1000 mcg beclomethasone-equivalent per
day) had a higher rate of positive sputum bacterial culture
than those on lower dose of ICS.
The largest study published to date that specifically
assessed pneumonia in COPD patients was conducted in
Table 6 Relationship between clinical outcomes of the patients and the sputum, NPA and serology results (the first admission
of the patients was assessed)
Sputum culture (NZ 71 patients) Viral PCR or viral culture or
serology (NZ 73 patients)
þve (nZ 29) ve (nZ 42) þve (nZ 12) ve (nZ 61)
Length of stay in acute hospital (days) 8.52 6.38 9.05 6.16 7.67 3.92 8.95 6.48
pZ 0.73 pZ 0.51
Length of stay in both acute and
convalescent hospital (days)
16.31 9.07 17.36 14.09 18.25 14.74 16.38 12.70
pZ 0.73 pZ 0.65
Required NPPV support 5 (17.2%) 8 (19.0%) 5 (41.7%) 7 (11.5%)
pZ 0.85 pZ 0.01*
Death in the same admission 3 (10.3%) 4 (9.5%) 1 (8.3%) 10 (16.4%)
pZ 0.93 pZ 0.51
Death in the next 12 months 8 (27.6%) 13 (31.0%) 4 (33.3%) 20 (32.8%)
pZ 0.76 pZ 0.97
Readmission in the next 12 months 15 (51.7%) 26 (61.9%) 8 (66.7%) 32 (52.5%)
pZ 0.39 pZ 0.37
*p Value <0.05.
NPPVZ non-invasive positive pressure ventilation.
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ical tests, the investigators identified infectious etiology
in 64% of the cases but their study did not include any viral
assessments.15 In our study, S. pneumoniae and P. aerugi-
nosa were the commonest bacteria identified, in contrast
to the findings by Torres et al. that the commonest organ-
isms were S. pneumoniae (43%) and C. pneumoniae (12%).
Atypical organisms (such as M. pneumoniae, C. pneumoniae
and L. pneumophila) were not detected by both serology
and NPA viral PCR in our study. A recent study that specif-
ically looked for atypical pathogens in patients with AE-
COPD without pneumonia has failed to identify these
organisms by sputum PCR assessment.24
Another study that involved 23 patients admitted with
‘‘pneumonic’’ AECOPD found that the infectious etiologies
(both bacterial and viral) were identified in 78% of the
patients using paired blood serology testing and the rate
was markedly higher than our findings.25 Our study subjects
had similar lung function (mean FEV1% predicted of about
40%) to the study by Torres et al., and the difference in re-
sults could not be explained on the basis of lung function.15
Previous studies on CAP not specific to COPD patients ob-
served a geographic difference in the bacterial etiologies.
For example, a study from Malaysia noted a higher preva-
lence of Gram-negative bacilli when compared to the west-
ern countries.7 It is uncertain whether geographic or other
factors could explain the differences in microbiology pat-
tern in the various studies.
Recently, the use of ICS has been implicated to increase
the risk of CAP among patients with COPD.4,26 However, the
mechanism underlying this observation is unclear. The in-
crease in pneumonia did not appear to represent an in-
crease in the number of deaths.26 We observed that
subjects on high dose ICS had a higher rate of positive
sputum bacterial culture than patients on low-medium
dose of ICS. Our observation concurred with that by Ernst
et al.4 that the adjusted risk ratio of hospitalization for
pneumonia was the greatest with the highest dose of ICSuse (>1000 mcg fluticasone equivalent dose per day). ICS
can decrease the inflammation in the airway.27 Whether
this decrease in inflammation, with possibly concomitant
decrease in defense against micro-organisms, could explain
the observation of a higher rate of positive sputum culture
in our patients with AECOPD and concomitant pneumonia
on high dose ICS, and the higher rate of pneumonia in
COPD patients on ICS,4,26 certainly requires further study.
Viruses are important causative agents for CAP. Among
the CAP patients (not specific for COPD patients) admitted
to hospital in Chile, respiratory viruses were found in 32% of
the patients using viral immunofluorescence assay of nasal
swabs, serology and urinary antigen.28 The commonest
virus identified in their study was parainfluenza viruses (in
17 samples), followed by influenza A (8 samples) in contrast
to our finding that influenza A virus was the commonest
virus. We have chosen viral PCR technique as the main
method of virus identification as we have demonstrated
previously that PCR technique had a 2.7 times higher diag-
nostic yield than conventional viral culture.11 It appears
that bacteria are far more common than viruses as the eti-
ological agents in patients with AECOPD and concomitant
pneumonia whereas the overlap between viral and bacteria
etiologies was also low (3.8%) in our study.
Our study is limited by the fact that this was a single
center study with a relatively small sample size. In
addition, lung function data were not available in 12
patients who had died before their scheduled lung function
appointments. Furthermore, NPA PCR was performed in this
study instead of sputum PCR. Sputum PCR assessment
probably would assess the lower respiratory tract infection
better than using NPA specimens. Previous studies using
both sputum and nasal lavage PCR have shown that the
diagnostic yield for AECOPD patients (without pneumonia)
were higher in induced sputum than in nasal lavage.13 Com-
parison of the infectious etiology of pneumonia in subjects
with and without COPD was not available as we had not
collected the clinical data and respiratory specimens from
Study of infectious etiology in patients with AECOPD and concomitant pneumonia 1115subjects with pneumonia but without COPD in this current
study. An early study of CAP in 90 subjects (13% with
chronic bronchitis) in Hong Kong in 1988 found that 41%
had identifiable etiologies but there was no comparison be-
tween subjects with and without COPD.29 Their etiologies
appeared different from ours, with S. pneumoniae and
Mycobacterium tuberculosis (each 12.2%) as the common-
est organisms.
In summary, an infectious etiology could be established
in about half of patients hospitalized with AECOPD and
concomitant pneumonia, and the majority of identifiable
causes were bacterial. We have observed that the use of
higher dose ICS was associated with a higher rate of positive
sputum bacterial culture in patients with AECOPD and
concomitant pneumonia. Further studies are needed to
investigate why COPD patients on ICS appear more prone to
pneumonia as reported by recent studies.4,26
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